156 related articles for article (PubMed ID: 17095910)
1. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
Vergès B
Curr Opin Lipidol; 2006 Dec; 17(6):653-8. PubMed ID: 17095910
[TBL] [Abstract][Full Text] [Related]
2. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
Sacks FM
Am J Cardiol; 2008 Dec; 102(12A):34L-40L. PubMed ID: 19084088
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
Steiner G
Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
[TBL] [Abstract][Full Text] [Related]
4. FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
Wierzbicki AS
Int J Clin Pract; 2006 Apr; 60(4):442-9. PubMed ID: 16620358
[TBL] [Abstract][Full Text] [Related]
5. Role for fibrate therapy in diabetes: evidence before FIELD.
Vergès B
Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials and lipid guidelines for type II diabetes.
Prisant LM
J Clin Pharmacol; 2004 Apr; 44(4):423-30. PubMed ID: 15051751
[TBL] [Abstract][Full Text] [Related]
7. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
Carrington M; Stewart S
Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072
[TBL] [Abstract][Full Text] [Related]
8. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
Allemann S; Diem P; Egger M; Christ ER; Stettler C
Curr Med Res Opin; 2006 Mar; 22(3):617-23. PubMed ID: 16574044
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
Bailey CJ
Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706
[No Abstract] [Full Text] [Related]
10. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
12. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
Wierzbicki AS
Curr Opin Cardiol; 2009 Jul; 24(4):372-9. PubMed ID: 19424060
[TBL] [Abstract][Full Text] [Related]
13. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Taskinen MR; Sullivan DR; Ehnholm C; Whiting M; Zannino D; Simes RJ; Keech AC; Barter PJ;
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):950-5. PubMed ID: 19325138
[TBL] [Abstract][Full Text] [Related]
14. Hyperlipidaemia and cardiovascular disease: do fibrates have a role?
Saha SA; Arora RR
Curr Opin Lipidol; 2011 Aug; 22(4):270-6. PubMed ID: 21519250
[TBL] [Abstract][Full Text] [Related]
15. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Cheng AY; Leiter LA
Curr Opin Cardiol; 2006 Jul; 21(4):400-4. PubMed ID: 16755211
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
17. [The FIELD study presented and published. Unconvincing results of fenofibrates in diabetic patients].
Widimský J
Vnitr Lek; 2006 Jan; 52(1):80-4. PubMed ID: 16526203
[TBL] [Abstract][Full Text] [Related]
18. ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients.
Aalbers J
Cardiovasc J Afr; 2010; 21(2):118-9. PubMed ID: 20532440
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate: treatment of hyperlipidemia and beyond.
Rosenson RS
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1319-30. PubMed ID: 19018684
[TBL] [Abstract][Full Text] [Related]
20. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
